$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Last Annual Value
13.71M
3-Year CAGR
130%
5-Year CAGR
65%
10-Year CAGR
28%
| Company | Total Other Income Expenses Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Sionna Therapeutics, Inc. NASDAQ:SION | 13.71M | 64.7% | N/A | N/A | |
![]() Vera Therapeutics, Inc. NASDAQ:VERA | 15.86M | 38.1% | 54.6% | N/A | |
![]() Janux Therapeutics, Inc. NASDAQ:JANX | 44.04M | 44.2% | 179.8% | N/A | |
![]() Maze Therapeutics, Inc. NASDAQ:MAZE | 11.78M | N/A | N/A | N/A | |
![]() Ardelyx, Inc. NASDAQ:ARDX | -19.65M | N/A | N/A | N/A | |
![]() Celldex Therapeutics, Inc. NASDAQ:CLDX | 28.60M | 29.7% | 124.2% | 20.6% | |
![]() Immunome, Inc. NASDAQ:IMNM | 1.72M | -14.2% | 28.4% | N/A | |
![]() Xeris Biopharma Holdings, Inc. NASDAQ:XERS | -24.34M | N/A | N/A | N/A | |
![]() Biohaven Ltd. NYSE:BHVN | 8.00M | -32.9% | 4.3% | N/A |
Continue your SION research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.